News

TEL：+86-21-33585366（DDT）
     34666753、33588661
FAX：+86-21-34979012
Q Q：  2762556331（Domestic）
      3501899018（Export）
E-mail：info@shyrchem.com
Domestic：sales@shyrchem.com
Export：sales02@shyrchem.com

Your current location：Home > News

Over $700 million collaboration to develop SSTR2 targeted nuclear drug 2024-11-20
Parkinson's disease new drug application accepted for market launch 2024-11-15
Targeting the Korean biopharmaceutical market 2024-11-11
The innovation progress of domestic medical devices is accelerating again! 2024-11-05
Sales of 19 diabetes drugs exceeded 100 million yuan 2024-11-01
Domestic pharmaceutical companies achieve win-win cooperation 2024-10-30
Multiple pharmaceutical CXO companies release positive signals in their third quarter reports 2024-10-25
The pharmaceutical sector is strengthening, with multiple stocks hitting the daily limit up! 2024-10-22
9 pharmaceutical stocks with a total market value exceeding 100 billion yuan 2024-10-18
The performance of various sub tracks in the pharmaceutical sector was prosperous in the third quart 2024-10-15

Pages：1/7 page10 total70 home last next end go to:

Copyright © 2017-2020 SHANGHAI YINGRUI BIOPHARMA CO.,LTD 沪ICP备11038445号-1
TEL：+86-21-33585366(DDT)、34666753 FAX：+86-21-34979012
E-mail：info@shyrchem.com ADD：1885 Metropolitan Road, Minhang District, Shanghai Code：201108